EMEA-002862-PIP01-20
Table of contents
Key facts
| Active substance |
COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0003/2021
|
| PIP number |
EMEA-002862-PIP01-20
|
| Pharmaceutical form(s) |
Concentrate for solution for injection
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
AstraZeneca AB
Tel. +46 855324400 E-mail: paediatrics@astrazeneca.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|